NCT05386888

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

A Phase 2 Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy for Patients With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Genfleet Therapeutics (Shanghai) Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).

Conditions

• NSCLC, Stage III

Interventions

Type	Name	Description
DRUG	GFH018	Administered as oral
DRUG	Toripalimab	Administered as an IV infusion
DRUG	Paclitaxel	Administered as an IV infusion
DRUG	Carboplatin	Administered as an IV infusion
DRUG	Cisplatin	Administered as an IV infusion
DRUG	Pemetrexed	Administered as an IV infusion
RADIATION	Thoracic Radiation Therapy (TRT)	Thoracic Radiation Therapy (TRT)
DRUG	GFH018	Administered as an IV infusion

Timeline

• Start date: 2022-09-09
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2022-05-23
• Last updated: 2025-10-02

Locations

1 site across 1 country: China